Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Date:11/30/2011

CAMBRIDGE, Mass., Nov. 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with one of multiple standard treatment regimens for patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with these separate chemotherapy regimens. Study sites in North America and the European Union are expected to participate in this trial.  The first patient was enrolled at Fox Chase Cancer Center in Philadelphia, PA.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. ... multi-product marketing agreement with development and manufacturing partner ... Under the terms of this agreement, Breckenridge will ... in the United States . ... tentatively-approved ANDA. The products cover a wide range ...
(Date:12/5/2016)... and PUNE, India , December ... report by Allied Market Research, titled, "Global Cancer Biomarkers Market ... revenue of cancer biomarkers market is projected to reach $15,737 ... CAGR of 13.3% from 2016 to 2022. Omic technologies segment ... 2015 and is expected to maintain its dominance during the ...
(Date:12/5/2016)... FRANCISCO , Dec. 5, 2016  Recently ... a methylation age predictor, known as Horvath,s Clock. ... offering a sample analysis service to academic and ... of any human sample, other than sperm. The ... to accurately estimate biological age versus chronological age ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” ... tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the social ... people will be diagnosed with epilepsy within their lifetime. With such a large ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... lines. The goal of Castlewood Treatment Centers has always been to promote the ... as many people as possible. In that spirit, Castlewood has announced two new ...
Breaking Medicine News(10 mins):